Business Wire

Blue Planet Prize 2025: Announcement of Prize Laureates

11.6.2025 04:00:00 CEST | Business Wire | Press Release

Share

This year marks the 34th awarding of the Blue Planet Prize, the international environmental award sponsored by the Asahi Glass Foundation, chaired by Takuya Shimamura. Every year, the Foundation selects two laureates, individuals, or organizations who have made significant contributions to the resolution of global environmental problems. The Board of Directors has selected the following 2025 Blue Planet Prize laureates.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603602267/en/

Professor Robert B. Jackson (USA)

1. Professor Robert B. Jackson (USA) Born on September 26, 1961
Department of Earth System Science, Stanford University

Professor Robert B. Jackson is an expert on the carbon cycle in terrestrial ecosystems, including forests, grasslands, and wetlands. He has conducted pioneering research on the relationship between soil, vegetation, and soil bacterial communities. In addition, he has quantified the balance of greenhouse gases, such as carbon dioxide, methane, and nitrous oxide, from natural ecosystems and from fossil fuel use. Since 2017, he has served as chair of the Global Carbon Project (GCP), leading efforts to monitor and reduce greenhouse gas emissions.

2. Dr. Jeremy Leggett (UK) Born on March 16, 1954
Founder and CEO of Highlands Rewilding Ltd.
Inaugural chairman of the Carbon Tracker Initiative

Dr. Jeremy Leggett, as the inaugural chairman of the Carbon Tracker Initiative (CTI), introduced the concept of the "carbon bubble," highlighting the economic risks associated with fossil fuel assets. Through CTI’s activities, he influenced investors and policymakers, advancing the divestment movement. In addition, as a practical effort to balance economic activity with environmental conservation, he founded one of the UK’s leading solar energy companies. More recently, he has been spearheading initiatives in Scotland to connect ecological restoration with community prosperity.

  • Each laureate is presented with a certificate of merit, a commemorative trophy, and 500,000 US dollars in prize money.
  • The Award Ceremony is scheduled on Wednesday, October 29, 2025, at Tokyo Kaikan. Commemorative lectures will be given on October 30th and November 1st, 2025, at the University of Tokyo and at the Kyoto International Community House (kokoka), respectively.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250603602267/en/

Contacts

Toshihiro Tanuma, PhD
THE ASAHI GLASS FOUNDATION
2nd Floor, Science Plaza, 5-3 Yonbancho Chiyoda-ku, Tokyo 102-0081 Japan
Phone +81-3-5275-0620
e-mail: post@af-info.or.jp
URL: https://www.af-info.or.jp/en/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.af-info.or
.jp%2Fen%2F&esheet=54264919&newsitemid=20250603602267&lan=en-US&anchor=https%3A%
2F%2Fwww.af-info.or.jp%2Fen%2F&index=1&md5=9e29736729569b4f682b605661e41837

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press Release

Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland required for equivalent yields and logistical carbon. Digital Reef CEO Piers Slater stated "Digital Reef embrace data centre growth and environment

SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press Release

SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5% 6% Income before taxes - GAAP basis $1,019 $1,018 $1,000 0% 2% Income before taxes margin - GAAP basis 10.8% 11.4% 11.2% -57 bps -42 bps Net income attributable to SLB - GAAP basis $735 $786 $739 -6% -1% Diluted EPS - GAAP basis $0.49 $0.52 $0.50 -6% -2% Adjusted EBITDA* $2,067 $1,899 $2,061 9% - Adjusted EBITDA margin* 21.9% 21.2% 23.1% 71 bps -121 bps Pretax segment operating income* $1,576 $1,404 $1,626 12% -3% Pretax segment operating margin* 16.7% 15.6% 18.2% 104 bps -153 bps Net income attributable to SLB, excluding charges & credits* $962 $833 $1,027

EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press Release

EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press Release

Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the company’s Injectable Aesthetics portfolio in China – one of the world's largest and fastest-growing aesthetics markets.8,9 This approval follows successful authorizations and launches of Relfydess in more than 35 markets worldwide. Relfydess is the first and only ready-to-use liquid neuromodulator developed with PEARL Technology, designed to deliver a highly active, innovative, complex-free molecule that addresses the real needs of patients and healthcare professionals.1,2,4,5 It is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.1,10 At a time whenpatients and healthcare professionals are increasingly seeking high-performance neuromodulators that rapidly deliver long-lasting, natural-looking outcomes, Re

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye